Click Here for 5% Off Your First Aladdin Purchase!

ABT-199 (GDC-0199) - ≥99%, high purity , Apoptosis regulator Bcl-2 inhibitor, CAS No.1257044-40-8, Apoptosis regulator Bcl-2 inhibitor

  • Moligand™
  • ≥99%
Item Number
A124869
Grouped product items
SKUSizeAvailabilityPrice Qty
A124869-5mg
5mg
In stock
$58.90
A124869-10mg
10mg
In stock
$82.90
A124869-25mg
25mg
In stock
$94.90
A124869-50mg
50mg
In stock
$105.90
A124869-100mg
100mg
In stock
$137.90
A124869-500mg
500mg
In stock
$621.90

Potent, selective Bcl-2 inhibitor.

Basic Description

SynonymsVenetoclax|1257044-40-8|ABT-199|Venclexta|GDC-0199|ABT199|ABT 199|venclyxto|RG7601|UNII-N54AIC43PW|GDC 0199|RG-7601|Venetoclax (ABT199)|N54AIC43PW|Venetoclax; Abt-199|Venetoclax(ABT-199)|4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperaz
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients wi
Storage TempProtected from light,Store at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST, INHIBITOR
Mechanism of actionApoptosis regulator Bcl-2 inhibitor
Product Description

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of <0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and preventing permeabilization of the mitochondrial outer membrane. This protein is tightly regulated for the homeostasis between cell growth and cell death.
A Bcl-2-selective inhibitor with Ki of <0.01 nM

Product Properties

ALogP8.2

Associated Targets

DRD1 Tclin D(1A) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BRD4 Tchem Bromodomain-containing protein 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR3 Tclin Fibroblast growth factor receptor 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CSNK1D Tchem Casein kinase I isoform delta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A2 Tclin Sodium-dependent noradrenaline transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A3 Tclin Sodium-dependent dopamine transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TRIM24 Tchem Transcription intermediary factor 1-alpha 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PGR Tclin Progesterone receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE3A Tclin cGMP-inhibited 3',5'-cyclic phosphodiesterase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS2 Tclin Prostaglandin G/H synthase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MCL1 Tchem Induced myeloid leukemia cell differentiation protein Mcl-1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MC3R Tchem Melanocortin receptor 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NR1I2 Tchem Nuclear receptor subfamily 1 group I member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CASP3 Tchem Caspase-3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BRPF1 Tchem Peregrin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BAD Tchem Bcl2-associated agonist of cell death 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCL2 Tclin Apoptosis regulator Bcl-2 10 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKA Tchem Aurora kinase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCL2L1 Tchem Bcl-2-like protein 1 10 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCL2L2 Tchem Bcl-2-like protein 2 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRB2 Tclin Beta-2 adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM1 Tclin Muscarinic acetylcholine receptor M1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ASPH Tchem Aspartyl/asparaginyl beta-hydroxylase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GSK3B Tclin Glycogen synthase kinase-3 beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPK1 Tchem Mitogen-activated protein kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488201440
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488201440
IUPAC Name 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
INCHI InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
InChi Key LQBVNQSMGBZMKD-UHFFFAOYSA-N
Canonical SMILES CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
Isomeric SMILES CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
PubChem CID 49846579
Molecular Weight 868.44

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

17 results found

Lot NumberCertificate TypeDateItem
K2208012Certificate of AnalysisAug 22, 2024 A124869
K2208013Certificate of AnalysisAug 22, 2024 A124869
K2208014Certificate of AnalysisAug 22, 2024 A124869
K2208015Certificate of AnalysisAug 22, 2024 A124869
E2224032Certificate of AnalysisMar 18, 2024 A124869
C1608065Certificate of AnalysisAug 08, 2023 A124869
I2122116Certificate of AnalysisJul 10, 2023 A124869
I2122117Certificate of AnalysisJul 10, 2023 A124869
E2320102Certificate of AnalysisMay 11, 2023 A124869
E2320108Certificate of AnalysisMay 11, 2023 A124869
E2320109Certificate of AnalysisMay 11, 2023 A124869
E2320112Certificate of AnalysisMay 11, 2023 A124869
E2320113Certificate of AnalysisMay 11, 2023 A124869
E2320114Certificate of AnalysisMay 11, 2023 A124869
E2322580Certificate of AnalysisMay 11, 2023 A124869
C2302802Certificate of AnalysisMar 15, 2023 A124869
K2208016Certificate of AnalysisOct 26, 2022 A124869

more

Chemical and Physical Properties

SolubilitySoluble in DMSO (100 mg/ml (~115mM) at 25 °C), water (<1 mg/ml (< 1mM) at 25 °C), and ethanol (<1 mg/ml (< 1mM) at 25 °C).
Sensitivitylight sensitive
Refractive Index1.64

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS07
Signal Danger
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H335:May cause respiratory irritation

H302:Harmful if swallowed

H372:Causes damage to organs through prolonged or repeated exposure

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352:IF ON SKIN: wash with plenty of water.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P271:Use only outdoors or in a well-ventilated area.

P270:Do not eat, drink or smoke when using this product.

P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P403+P233:Store in a well-ventilated place. Keep container tightly closed.

P362+P364:Take off contaminated clothing and wash it before reuse.

P330:Rinse mouth.

P203:Obtain, read and follow all safety instructions before use.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P301+P317:IF SWALLOWED: Get medical help.

P318:if exposed or concerned, get medical advice.

P337+P317:If eye irritation persists: Get medical help.

P332+P317:If skin irritation occurs: Get medical help.

P319:Get medical help if you feel unwell.

Related Documents

References

1. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al..  (2013)  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets..  Nat Med,  19  (2): (202-8).  [PMID:23291630]
2. Tian BP, Xia LX, Bao ZQ, Zhang H, Xu ZW, Mao YY, Cao C, Che LQ, Liu JK, Li W et al..  (2017)  Bcl-2 inhibitors reduce steroid-insensitive airway inflammation..  J Allergy Clin Immunol,  140  (2): (418-430).  [PMID:28043871]
3. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J et al..  (2018)  Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia..  N Engl J Med,  378  (12): (1107-1120).  [PMID:29562156]

Solution Calculators